Contracted Revenue of
Pipeline Revenue of
Distribution Partners Grew 15.9% Year Over Year
Third Quarter and Nine-Month 2026 Highlights
Distribution Partners , including brokers, third-party administrators ("TPAs") and agencies, reached 984 as ofSeptember 30, 2026 , an increase of 15.9% year over year.- Q3 2026 Revenue was
$6.6 million , compared with$8.5 million in Q3 2025. Nine-month 2026 revenue was$23.4 million , compared with$25.8 million in the prior year period. - Contracted Revenue1 totaled
$32.7 million for the first nine months of 2026, of which$24.4 million was recognized as GAAP revenue, before the enrollment adjustment and refund liability. The remaining$6.1 million and$2.2 million are expected to be recognized as GAAP revenue in the fourth quarter of 2026 and in 2027, respectively. - Pipeline Revenue2 as of
October 30, 2026 was$156.4 million , of which$2.6 million was contracted subsequent to quarter end. The remaining$153.8 million represents policies in quoting or binding status, with an expected conversion rate of 3% to 7%. - Net Loss for Q3 2026 was
$7.1 million , or$(0.11) per diluted share, and included a provision for credit losses of$5.3 million , compared to net income of$0.5 million , or$0.01 per diluted share, in Q3 2025. Net loss for the first nine months of 2026 was$11.2 million , or$(0.18) per diluted share, and included a provision for credit losses of$6.1 million , compared to net income of$1.6 million , or$0.03 per diluted share, for the first nine months of 2025. - Adjusted EBITDA3 was
$(3.9) million for Q3 2026 and$(6.6) million for the first nine months of 2026, reflecting continued investment in distribution, technology, and product development. - Platform Placed Plan Value ("PPPV")4 was
$91.8 million as ofSeptember 30, 2026 . - Cash balance was
$10.1 million as ofSeptember 30, 2026 .
CEO Commentary
"It is a privilege to lead
During 2026, the Company has invested in expanding its distribution network, strengthening carrier and strategic partnerships, and advancing new technology and products. Our existing eDIYBS and SMR platforms, together with HitRix, HitChain and the Three-Year Rate Stabilization Program, provide multiple avenues for future growth. As we move into 2027, our focus will increasingly shift toward commercialization, disciplined execution, and generating measurable returns from these investments.
Since assuming the CEO role, I have initiated a comprehensive review of our commercial operations, organizational capabilities, cost structure, and capital allocation priorities. We are focused on strengthening commercial execution, improving operating efficiency, and scaling our existing businesses. At the same time, we will evaluate strategic acquisitions, partnerships, and other expansion opportunities that could complement our platform, accelerate growth, and enhance long-term shareholder value. We expect to provide a more detailed update on our strategic priorities when we report our full-year 2026 results.
With Tim continuing to lead long-term strategy, technology innovation, and product development as Executive Chairman, we have an opportunity to combine his deep insurance industry expertise and entrepreneurial vision with my experience in business scaling, capital markets, and strategic execution. Our objective is to transform the strong foundation we believe
Corporate and Strategic Highlights
- HitRix Launch. Launched HitRix in
September 2026 , an AI-powered, broker-first marketplace designed to modernize the large-group self-funded stop-loss insurance placement process. By automating data ingestion, streamlining submissions across multiple carriers and managing general underwriters ("MGUs"), and enabling more efficient proposal comparisons, HitRix aims to reduce manual workflows, enhance broker productivity, improve quoting efficiency, and drive higher policy placement conversion rates. - Three-Year Rate Stabilization Program. The Company continues to advance its Three-Year Rate Stabilization Program, designed to provide employers with greater predictability in stop-loss insurance costs over a multi-year period. The Company has secured its first client. With the initial launch targeted by year-end 2026, the Company is prioritizing disciplined execution and aims to establish a foundation for converting its pipeline into future commercial growth.
- Strategic Leadership Transition. Appointed
Sanjay Shrestha as Chief Executive Officer, effectiveOctober 20, 2026 , to lead commercial execution, business expansion, and strategic growth.Mr. Shrestha brings extensive experience in public-company leadership, capital markets, and strategic acquisitions, as well as an established understanding ofHealth In Tech through both his prior service as a member of our Board and, later, as a strategic advisor to our Board. FounderTim Johnson transitioned to Executive Chairman to focus on long-term strategy, technology innovation, and product development. - Strengthened Board Expertise. Elected
Tim Cortes as an independent director at the Company'sNovember 10, 2026 Annual Meeting of Stockholders, bringing extensive technology and engineering leadership experience to our Board. - Updated 2026 Revenue Outlook. The Company revised its full-year 2026 revenue outlook to approximately
$30 million , modestly below 2025 revenue. The revision primarily reflects the delayed commencement of certain new policies resulting from the transition to a new carrier, which temporarily extended underwriting and onboarding timelines. These delays shifted the anticipated revenue contribution from certain new business opportunities into 2027, rather than reflecting a loss of the underlying opportunities. With the carrier transition substantially completed, the Company is focused on accelerating policy onboarding, improving conversion rates, and translating its existing pipeline into revenue growth in 2027.
End Notes
- Contracted Revenue is a period-based operating metric and is not a point-in-time backlog measure. Contracted Revenue includes contractual revenue associated with policies that are in force at any time during the applicable reporting period. For each such policy, Contracted Revenue includes: contractual revenue attributable to the portion of the policy term falling within the reporting period, including the amount recognized as GAAP revenue during the reporting period; and remaining contractual revenue expected to be recognized in future periods over the remaining contractual term of that policy. Revenue attributable to periods before the beginning of the applicable reporting period is excluded. A policy that expired or lapsed before the beginning of the reporting period is also excluded. If a policy expires or lapses during the reporting period, Contracted Revenue includes revenue attributable to that policy only through its expiration or lapse date, and no revenue is included for periods thereafter. Standard self-funded plan policies generally have a contractual term of 12 months, while our Three-Year Rate Stabilization Program is designed with a 36-month contractual term. Revenue is recognized under
U.S . GAAP on a straight-line basis over the policy term, beginning on the policy's effective date. Accordingly, Contracted Revenue includes contractual revenue associated with policies that are in force at any time during the applicable reporting period. If a policy expires or lapses during the reporting period, Contracted Revenue includes revenue attributable to that policy only through its expiration or lapse date, and no revenue is included for periods thereafter. Contracted revenue is presented prior to the impact of monthly employers' enrollment adjustments during the contractual period, including changes in enrolled employees, plan mix, and other factors that may affect premium and fees. Accordingly, actual revenue recognized in future periods may differ from Contracted Revenue. Contracted Revenue is an operating metric and is not a substitute for GAAP revenue. - Pipeline Revenue represents revenue from self-funded plan policies that are being quoted, are in binding status, or have been contracted subsequent to the end of the reporting period. This metric reflects the entire contractual term of the underlying policies, some of which may not ultimately convert to revenue.
- Adjusted EBITDA is a non-GAAP financial measure. Additional information and reconciliation of Adjusted EBITDA to its most comparable GAAP financial measure is provided in the "Reconciliation of Net (Loss) Income Attributable to Common Stockholders to Adjusted EBITDA" section of this release.
- Platform Placed Plan Value ("PPPV") represents the aggregate contractual value of self-funded health plans with stop-loss insurance (self-funded stop-loss plans) placed through the Company's platform during the fiscal year through the applicable fiscal quarter end, measured over each plan's full contractual term of typically 12 or 36 months from the plan's effective date. PPPV reflects the total economic value flowing through the platform, including premium, claim funding, and administrative fees, and is a measure of platform transaction volume rather than an indication of the Company's own revenue or take rate.
Conference Call Details
A live audio webcast will be available via the Investor Relations page of
Non-GAAP Financial Information
This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in
Use of Forward-Looking Statements
Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the
These forward-looking statements are based on current expectations and beliefs concerning future events and developments and their potential effects on
Any forward-looking statement made in this press release speaks only as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible for
About
| | ||||
| Consolidated Statements of Operations | ||||
| (Unaudited) | ||||
| | ||||
| | Three Months Ended | Nine Months Ended | ||
| | 2026 | 2025 | 2026 | 2025 |
| Revenues | | | | |
| Revenues from underwriting modeling (ICE) | | | | |
| Revenues from fees (SMR) | 5,954,439 | 7,100,489 | 20,041,244 | 19,986,762 |
| Total revenues | 6,587,052 | 8,490,093 | 23,415,318 | 25,818,926 |
| | | | | |
| Cost of revenues | 3,524,692 | 3,346,277 | 11,921,066 | 9,009,841 |
| | | | | |
| Gross profit | 3,062,360 | 5,143,816 | 11,494,252 | 16,809,085 |
| | | | | |
| Operating expenses | | | | |
| Sales and marketing expenses | 2,061,695 | 962,567 | 6,569,185 | 3,279,560 |
| General and administrative expenses | 3,116,656 | 3,455,996 | 10,104,489 | 10,472,224 |
| Provision for credit losses | 5,337,768 | (4,089) | 6,074,587 | 1,901 |
| Research and development expenses | 938,564 | 235,819 | 2,734,770 | 1,356,149 |
| Total operating expenses | 11,454,683 | 4,650,293 | 25,483,031 | 15,109,834 |
| | | | | |
| Other income (expense): | | | | |
| Interest income | 64,627 | 111,699 | 201,666 | 305,263 |
| Interest expense | (20,000) | — | (20,000) | — |
| Financing transaction costs | (799,630) | — | (799,630) | — |
| Change in fair value of SEPA derivative liability | (2,235) | — | (2,235) | — |
| Change in fair value of convertible notes – FVO | (69,502) | — | (69,502) | — |
| Other income | 310 | — | 122,644 | 118,399 |
| Other expense | (35,375) | (5,000) | (87,716) | (5,000) |
| Total other income (expense), net | (861,805) | 106,699 | (654,773) | 418,662 |
| (Loss) income before income tax expense | (9,254,128) | 600,222 | (14,643,552) | 2,117,913 |
| Income tax benefit (expense) | 2,147,653 | (148,046) | 3,437,610 | (536,514) |
| | | | | |
| Net (loss) income | (7,106,475) | 452,176 | (11,205,942) | 1,581,399 |
| Net loss attributable to noncontrolling interests | (40,062) | — | (40,224) | — |
| | | | | |
| Net (loss) income attributable to common stockholders | | | | |
| | | | | |
| Net (loss) income per share | | | | |
| Basic | | | | |
| Diluted | | | | |
| | | | | |
| Weighted average common shares outstanding: | | | | |
| Basic | 63,078,291 | 56,432,407 | 61,107,984 | 55,484,860 |
| Diluted | 63,078,291 | 58,774,334 | 61,107,984 | 57,477,873 |
| Reconciliation of Net (Loss) Income Attributable to Common Stockholders to Adjusted EBITDA | ||||
| (Unaudited) | ||||
| | ||||
| | Three Months Ended | Nine Months Ended | ||
| | 2026 | 2025 | 2026 | 2025 |
| Net (loss) income attributable to common stockholders | | | | |
| Interest income | (44,627) | (111,699) | (181,666) | (305,263) |
| Amortization expense | 278,747 | 217,981 | 1,002,534 | 489,947 |
| Income tax (benefit) expense | (2,147,653) | 148,046 | (3,437,610) | 536,514 |
| Stock-based compensation expense, including employer payroll | 730,041 | 292,552 | 2,133,849 | 1,493,686 |
| Provision for credit losses on other receivables | 2,582,529 | — | 3,322,302 | — |
| Provision for credit losses on loans receivable | 863,992 | — | 863,992 | — |
| Financing transaction costs | 799,630 | — | 799,630 | — |
| Change in fair value of SEPA derivative liability | 2,235 | — | 2,235 | — |
| Change in fair value of convertible notes – FVO | 69,502 | — | 69,502 | — |
| Other non-recurring items | — | — | 37,341 | — |
| Total net adjustments | 3,134,396 | 546,880 | 4,612,109 | 2,214,884 |
| | | | | |
| Adjusted EBITDA | | | | |
| Consolidated Balance Sheets | ||
| (Unaudited) | ||
| | ||
| | | |
| | 2026 | 2025 |
| Assets | | |
| Current assets | | |
| Cash and cash equivalents | | |
| Accounts receivable, net of allowance for credit losses of | 3,177,652 | 756,288 |
| Loans receivable, net of allowance for credit losses of | — | 815,995 |
| Other receivables, net of allowance for credit losses of | 1,669,747 | 3,467,814 |
| Deferred offering costs | 180,987 | 170,977 |
| Prepaid expenses and other current assets | 1,933,469 | 3,280,148 |
| Total current assets | 17,089,092 | 16,160,976 |
| Non-current assets | | |
| Software | 8,148,785 | 6,530,894 |
| Operating lease - right-of-use assets | 85,776 | 139,940 |
| Long-term prepaid expenses | 17,956 | 258,151 |
| Deferred tax assets, net | 2,691,345 | — |
| Total non-current assets | 10,943,862 | 6,928,985 |
| Total assets | | |
| | | |
| Liabilities and stockholders' equity | | |
| Current liabilities | | |
| Accounts payable and accrued expenses | | |
| SEPA derivative liability | 82,629 | |
| Convertible notes payable, at fair value | 6,639,108 | |
| Operating lease liabilities - current | 83,831 | 76,195 |
| Other current liabilities | — | 891,598 |
| Total current liabilities | 15,153,831 | 5,156,604 |
| Non-current liabilities | | |
| Deferred tax liabilities | — | 757,675 |
| Operating lease liabilities - non-current | — | 63,617 |
| Total non-current liabilities | — | 821,292 |
| Total liabilities | 15,153,831 | 5,977,896 |
| | | |
| Stockholders' equity | | |
| Common stock, | | |
| Common stock, | 11,700 | 11,700 |
| Additional paid-in capital | 18,727,294 | 11,834,121 |
| (Accumulated deficit) retained earnings | (5,945,480) | 5,220,238 |
| Noncontrolling interests | 32,008 | — |
| Total stockholders' equity | 12,879,123 | 17,112,065 |
| Total liabilities and stockholders' equity | | |
| Consolidated Statements of Cash Flows | ||||
| (Unaudited) | ||||
| | ||||
| | Three Months Ended | Nine Months Ended | ||
| | 2026 | 2025 | 2026 | 2025 |
| Cash flows (used in) provided by operating activities: | | | | |
| Net (loss) income | | | | |
| Adjustments to reconcile net (loss) income to net cash (used in) provided | | | | |
| Bad debt expense (recovery) | 1,891,247 | (4,089) | 1,888,293 | 1,901 |
| Amortization expense | 278,747 | 217,981 | 1,002,534 | 489,947 |
| Provision for refund liability | 383,854 | 1,413,345 | 492,256 | 2,369,088 |
| Provision for credit losses on other receivables | 2,582,529 | — | 3,322,302 | — |
| Provision for credit losses on loans receivable | 863,992 | — | 863,992 | — |
| Deferred tax (benefit) expense | (2,150,909) | 12,680 | (3,449,020) | (53,867) |
| Interest expense (income), net | 4,001 | (16,003) | (27,997) | (48,001) |
| Financing transaction costs | 799,630 | — | 799,630 | — |
| Change in fair value of SEPA derivative liability | 2,235 | — | 2,235 | — |
| Change in fair value of convertible notes – FVO | 69,502 | — | 69,502 | — |
| Stock-based compensation expense | 728,571 | 292,552 | 2,054,453 | 1,493,686 |
| Changes in operating assets and liabilities: | | | | |
| Accounts receivable | 3,477,408 | 416,592 | (4,309,657) | 776,574 |
| Other receivables | (1,116,876) | (16,272) | (1,188,320) | (3,370,854) |
| Prepaid expenses and other assets | 288,402 | (335,424) | 1,086,441 | (897,331) |
| Operating lease right-of-use assets and liabilities, net | (606) | 18 | (1,817) | 55 |
| Accounts payable and accrued expenses | (1,636,874) | (224,639) | 2,727,926 | 2,045,258 |
| Income taxes payable | — | (34,944) | — | (205,253) |
| Other current liabilities | (403,854) | (1,500,000) | (1,403,854) | (1,500,000) |
| Net cash (used in) provided by operating activities | (1,045,476) | 673,973 | (7,277,043) | 2,682,602 |
| | | | | |
| Cash flows used in investing activities: | | | | |
| Development of software | (842,164) | (744,841) | (1,801,287) | (2,358,213) |
| Net cash used in investing activities | (842,164) | (744,841) | (1,801,287) | (2,358,213) |
| | | | | |
| Cash flows provided by (used in) financing activities: | | | | |
| Proceeds from issuance of common stock in connection | — | — | 6,381,000 | — |
| Proceeds from the issuance of convertible notes payable, | 6,650,000 | — | 6,650,000 | — |
| Payments of deferred offering costs | (230,027) | (43,685) | (473,635) | (150,024) |
| Payments of financing costs related to SEPA and convertible notes | (580,000) | — | (580,000) | — |
| Contributions from noncontrolling interests | — | — | 71,428 | — |
| Taxes paid related to net share settlement of equity awards | (339,909) | — | (512,980) | — |
| Net cash provided by (used in) financing activities | 5,500,064 | (43,685) | 11,535,813 | (150,024) |
| | | | | |
| Increase (decrease) in cash and cash equivalents | 3,612,424 | (114,553) | 2,457,483 | 174,365 |
| Cash and cash equivalents, beginning of the period | 6,514,813 | 8,138,166 | 7,669,754 | 7,849,248 |
| Cash and cash equivalents, end of the period | | | | |
| | | | | |
| Supplemental disclosures of cash flow information: | | | | |
| Cash paid for interest | | $ — | | $ — |
| Cash paid for income taxes | $ — | | | |
| | | | | |
| Summary of noncash investing and financing activities: | | | | |
| Accrued deferred offering costs included in accounts payable and | | | | |
| Accrued development of software included in accounts payable | 800,058 | 401,964 | 800,058 | 401,964 |
| Accrued financing costs in accounts payable and accrued expenses | 219,630 | — | 219,630 | — |
| Reclassification of deferred offering costs to additional paid-in capital | — | — | 527,910 | — |
| Stock-based compensation capitalized for software development | 17,978 | — | 37,432 | — |
Investor Contact:
Health In Tech Investor Relations
ir@healthintech.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/health-in-tech-reports-third-quarter-2026-financial-results-302938411.html
SOURCE